CoChat
Sign Up
Cited by 355Cannabis and Cannabinoid ResearchParkinson's Disease Mechanisms and TreatmentsSchizophrenia research and treatment

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Cannabidiol for the treatment of psychosis in Parkinson's disease

Zuardi, AW, Crippa, Jas, Hallak, JEC, Pinto, JP, Chagas, MHN, Rodrigues, GGR, Dursun, SM, Tumas, V.·2009·Journal of Psychopharmacology
DOI 10.1177/0269881108096519
Open this paper in CoChat — free account

Abstract

The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study. Six consecutive outpatients (four men and two women) with the diagnosis of PD and who had psychosis for at least 3 months were selected for the study. All patients received CBD in flexible dose (started with an oral dose of 150 mg/day) for 4 weeks, in addition to their usual therapy. The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881108096519

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 7

  1. Bech, P., 1986, Acta Psychiatr Scand Suppl, 326, 1
  2. 10.1111/j.1460-9568.1998.00292.x · DOI
  3. Fahn, S., Elton, RL Members of the UPDRS Development Committee ( 1987) Unified Parkinson’s Disease Rating Scale (UPDRS) . In: Fahn, S, Marsden, CD, Calne, DB , Goldstein, M (eds), Recent Developments in Parkinson’s Disease, Vol. 2. Florahm Park, NJ: Macmillan Health Care Information , pp. 153-164.
  4. First, MB, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders - Clinician Version (SCID-CV)
  5. National Institute of Mental Health (1976) CGI - Clinical Global Impression. In: Guy, W (ed), ECDEU Assessment Manual of Psychopharmacology (revised) . Rockville, MD: NIMH, pp. 534- 537.
  6. Zuardi, AW, 1994, Rev ABPAPAL, 16, 63
  7. Zuardi, AW, 1995, J Clin Psychiatry, 56, 485

Cited by

Sorted by citations

See all 355

Related

See all

Metadata

Authors
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V.
Affiliations
  • Universidade de São Paulo (BR)
  • Department of Neuropsychiatry and Medical Psychology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
  • Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
Corresponding author
Zuardi, AW
ORCID
Tumas, V.
Venue
Journal of Psychopharmacology
Publisher
SAGE Publications
Published
2008-09-18
Volume
23
Issue
8
Pages
979-983
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
DOI
10.1177/0269881108096519
OpenAlex
W1967281437
Cited by
355
References
30
Citations by year
2026: 14 · 2025: 15 · 2024: 28 · 2023: 34 · 2022: 28 · 2021: 33 · 2020: 39 · 2019: 29 · 2018: 21 · 2017: 20 · 2016: 17 · 2015: 12 · 2014: 14 · 2013: 8 · 2012: 9
FWCI
7.24
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
Funders
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • National Institutes of Health
  • National Institute of Mental Health
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
cannabidiol, Parkinson's disease, psychosis, antipsychotic drugs, neuroprotection, motor function, drug safety and tolerability, Brief Psychiatric Rating Scale
MeSH terms
Adult, Aged, Cannabidiol, Female, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Psychotic Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review